FY2025 EPS Estimates for Hologic Raised by Leerink Partnrs

Key Points

• Hologic's FY2025 EPS estimates were raised by Leerink Partners to $4.25 per share from a previous estimate of $4.21, while the current consensus estimate is $4.28 per share.
• Citigroup upgraded Hologic from a "neutral" to a "buy" rating, increasing its price target from $60.00 to $80.00, while other firms also noted adjustments in their target prices.
• Hologic's quarterly earnings report for July 30th showed an EPS of $1.08, exceeding analysts' expectations of $1.05, with quarterly revenue reaching $1.02 billion.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Leerink Partnrs lifted their FY2025 EPS estimates for Hologic in a note issued to investors on Wednesday, July 30th. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will post earnings per share of $4.25 for the year, up from their prior forecast of $4.21. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic's Q4 2025 earnings at $1.11 EPS, Q3 2026 earnings at $1.19 EPS, Q4 2026 earnings at $1.14 EPS and FY2026 earnings at $4.55 EPS.

HOLX has been the subject of a number of other reports. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and boosted their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Royal Bank Of Canada reduced their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $76.42.

Hologic Stock Up 0.5%

HOLX traded up $0.34 during trading on Friday, hitting $67.16. The company had a trading volume of 1,863,529 shares, compared to its average volume of 1,799,668. The company has a market cap of $14.97 billion, a PE ratio of 27.87, a P/E/G ratio of 2.43 and a beta of 0.49. The business has a 50-day moving average of $64.42 and a 200-day moving average of $62.77. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.52. Hologic has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.06 earnings per share.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director owned 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.88% of the company's stock.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently bought and sold shares of the company. Chung Wu Investment Group LLC bought a new position in Hologic in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its stake in Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 273 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in Hologic in the first quarter valued at approximately $34,000. Cromwell Holdings LLC raised its holdings in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares during the period. Finally, Allworth Financial LP lifted its stake in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.